Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 2/20 | 0.45 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | PDE5A | O76074 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 3/20 | 0.39 |
| ▸ | MAOA | P21397 | 2/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | CCR2 | P41597 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.36 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL430829 | 0.81 | RIPK1 (0.50) | RIPK1NTRK1JAK2PDE5AOPRK1 | |
| SCHEMBL451781 | 0.81 | RIPK1 (0.50) | RIPK1NTRK1JAK2PDE5AOPRK1 | |
| SCHEMBL21723215 | 0.81 | RIPK1 (0.50) | RIPK1NTRK1JAK2PDE5AOPRK1 | |
| SCHEMBL29744544 | 0.81 | RIPK1 (0.50) | RIPK1NTRK1JAK2PDE5AOPRK1 | |
| SCHEMBL18555578 | 0.80 | NTRK1 (0.43) | RIPK1NTRK1JAK2 | |
| SCHEMBL18555577 | 0.80 | NTRK1 (0.43) | RIPK1NTRK1JAK2 | |
| SCHEMBL12478217 | 0.78 | NTRK1 (0.40) | RIPK1NTRK1JAK2OPRK1MAOB | |
| SCHEMBL4289056 | 0.77 | MAOB (0.45) | RIPK1NTRK1JAK2OPRK1MAOB | |
| SCHEMBL30898796 | 0.74 | NTRK1 (0.47) | RIPK1NTRK1JAK2PDE5AMAOB | |
| SCHEMBL23632045 | 0.74 | NTRK1 (0.47) | RIPK1NTRK1JAK2PDE5AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234955-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS | ARRAY BIOPHARMA INC (US) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234955-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS | TYMP, TYMS, TK1 | RIPK1 3419/4885NTRK1 1703/4885JAK2 1795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.